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M URINE MONOCLONAL antibody OKTJ (ortho-
clone OKT3). is a powerful immunosuppressant and 
has been shown to be very effective in reversal of acute 
rejection following kidney, liver a nd heart transplants. I·) 
As with any kind of immunosuppression, one would expect 
that use of OKTJ might be associated with increased inci-
dence of infections. However, there have been only a few 
detailed studies of infections following the usc of OKTJ and 
even fewer comparing them to infections that occur when 
steroids only were the mainstay of anti-rejection therapy.,·5 
Hence we undertook a detailed retrospective review of infec-
tions that occurred in children receiving OKT3 for hepatic 
allograft rejection and compared them to infections that 
occurred in a similar group of children whose rejection was 
treated with steroids only. 
PATIENTS AND METHODS 
Eighty cases were reviewed from a group of pediatric patients having 
li~er transplants at the Children's Hospital of Pittsburgh and the 
University of Pittsburgh betlloeen January 198 I and June 1986. To 
be included. patients should have received treatment for clinical or 
biopsy proven rejection within six months following the primary 
transplant and survived for at least seven or more days upon its 
completion. Patients were excluded if rejection therapy was aborted 
« 7 doses of OK T3 or less than 3 days of steroids in a five day oral 
recycle). or if they received polyclonal antilymphocyte globulin. 
Symptomatic infections lIoere identified and grouped by strict adher-
ence to predefined criterta. The study spanned two periods of 
rejection therapy. Until October 1984. study patients received only 
addilional sleroids to treat rejection. From October 1984. OKT3 
became available to treat rejection either alone. or in addition to 
steroids. The paticnl's course was rc:vie"'c:d from the time of trans-
plant. up to 1 gOdays or 90 days after completion of rejection therapy 
",hichevcr was longer. Data on pre-transplant characteristics. tech-
nical complications. infections. lotal amount of immunosuppression. 
retransplants and deaths were collected. 
Statistical Analysis 
Analyses "'cre performed on a mainframc computer using a statisti-
cal program for social sciences (SPSS) for comparing proportions 
and student's t-test for comparing mean values. P values or <0.05 
were considered significant. 
RESULTS 
Twenty-seven patients had rejection treated with onl)' addi-
tional steroids. Fifty-three received OKTJ as part of their 
rejection treatment. The patient characteristics in both 
groups arc outlined in Table I. 
Immunosuppression 
Baseline immunosuppression was essentially similar in both 
groups and has been described in detail before.' Maintenance 
cyclosporine (CyA) and steroids were continued during 
OKT3 treatment. Twenty of twenty·seven patients in steroid 
group and 27/53 in OK TJ selected at random. had their total 
amount of intravenous and oral CyA. bolus steroids and 
prednisone calculated for the entire follow-up period as mean 
dose in mg/kg/day. These values shown in Table I. showed 
no statistical significance between the groups. 
Infections 
The overall infection rate in the steroids only group was 
66.6% (18/27). Viral infections occurred in 37% (10/27). 
fungal infections in 14.8% (4/27) and bacterial infections in 
44.4% (12/27) of patients. Compared to this viral infections 
occurred in 45.2%. (24/53). fungal infections in 20.7% 
(II/53) and bacterial infections in 47.1 % (25/53) of patients 
receiving OKT3. Two in the OKTJ group (3.7%) but none in 
the steroid group developed pneumocystis pneumonitis. 
These results are tabulated in Table 2. There is no statisti-
cally significant difference between the two groups either in 
the overall incidence of infections or in specific occurrence of 
viral. fungal or bacterial infections .. 
Technical Complications 
In the steroid group. 9 patients (33%) had 12 technical 
complications whereas 18 in OKT3 group (34%) had 31 
complications. The o\erall infection rates in both groups 
were the same EUUKU~FK The majority of the infections in this 
subgroup of patients were bacterial. 
Retransplants and Dealhs 
Seven patients in the steroids group required 9 retransplants 
during the follow-up period. Approximately half of them 
(5/9) were for rejection. In the OKT3 group, 15 patients 
required 16 retransplants. 6/16 were for rejection. Three 
deaths occurred in the steroid group versus II in the OKT3 
group. Two of the deaths in the steroid group and 9 of the 
deaths in the OKT3 group were directly attributable to 
infection. There was no statistical significance either in the 
rate of retransplants or deaths between the two groups. 
From the Department of Surgery. The Universily of Pillsburgh 
School of Medicine and the Children's Hospital of Pillsburgh. 
Pittsburgh, PA. USA. 
Address reprint requests to Baburao Koneru. MD. Universily 
Hospilal. Departmenl 01 Surgery·E325. 150Bergen St, Newark NJ 
07103. USA. 
Supported by Research GranlS from the Veterans Administra· 
tion Project Granl OK 29961 Irom the National Institutes of Health, 
Be:hesda, Maryland. USA. 
e 1989 by Appleton & Lange. Inc. 
0041-1345/89/$3.001 +0 
Transplantation Proc •• dings. Vo121. No 1 (February). 1989: pp 2251-2252 2251 
K--"K----~-
· -----------
2252 
Table 1. CharacterllUes of the Patient. 
Treated for Rejection 
Mean age (months) 
Sex males:lemales 
Mean weight (kg) 
Pretransplant (mean values) 
WBC/mm' 
Steroid. Only 
(n - 27) 
60 
13: 14 
16 .• 
6.08 
OKT3 
(n - 63) 
66 
26:27 
19.7 
7." 
Total bilirubin mg/dl 18 18.1 
Prothrombin time in sec. 16.1 16.8 
Biliary atresia 55% 45% 
Prior abdominal surgery 55% 56% 
Immunosuppression given as mgm/kg/d (mean values) 
I.V. CyA 1.29 1.49 
P.O. CyA 19.8 29.2 
Bolus steroida 0.92 0.85 
Oral prednisone 
Mean lollow·up days 
DISCUSSION 
1.31 
171 
1.21 
161 
Most of the reports describing the clinical use of OKT3 have 
dealt with its efficacy in reversing established allograft 
reject ions. 1.1.' The problems of infections had not been 
reported in detail. Since then a few reports have studicd the 
topic of infections in renal recipients. Sanoh et al in their 
comparison of infections in 2 groups of renal recipients with 
acute rejection treated and not treated with OKT3 found 
higher incidence of viral and bacterial infections in the 
OKT3 group.s The number of cases with fungal infections 
were too small to compare. 
In adult liver recipients receiving OKT3. Singh et al 
reported a higher incidence and more serious infections with 
herpes group of viruses.' However. the other patients in that 
report have nct all been treated for rejection. In 51 consecu-
tive pediatric liver recipients Breinig et al showed a different 
pattern of viral infections compared to adults.' Fewer of 
them had primary CMV and HSV infections. Adenoviral 
infections. not seen in adult liver recipients. were encoun-
tered. 
Our study shows no difference in the overall rate of 
infections between the two groups of patients. This is still 
true even when individual categories of infections are consid-
ered separately (Table 2). Liver transplant patients also have 
higher incidence of fungal infections compared to other 
organ allograft recipients. This is probably related to higher 
incidence of technical problems and longer operative time in 
liver recipients.' Fungal infections also increase with 
increased amounts of steroids. The incidence of fungal 
infections in our two groups of patients were similar and were 
not statistically significant (14.8% in steroids versus 20. T~ in 
OKT3). 
Pediatric liver recipients have higher incidence of techni-
cal complications compared to adults. 1o These patients 
develop a variety of fungal and bacterial infections. The 
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Table 2. Various Infections Encountered In Patient. 
Treated for Rejection 
Total number of palienlS wilh in·· 
fections 
Patients with viral infections 
Cytomegalovirus 
Herpes simplex virus (HSV) 
Adenovirus (A V) 
Varicella zoster 
Epstein·Barr virus (EBV) 
Parainftuenza 
Patients with fungal infections 
Candida 
Aspergillus 
Nocardia 
Patients with bacterial infec· 
tions 
Steroida Only 
n - 27 
18 (66.6%) 
10 (37%) 
3 
4 
4 (t 4.8%) 
3 
12 (44.<4%) 
OKT3 
n - 53 
36 (67.9%) 
24 (45.2%) 
10 
8 
4 
1 
4 
1 
1 1 (20.7%) 
10 
2 
25 (.7.1otb) 
overall incidence of infections in patients with technical 
complications in the present series has been very high but it is 
the same in both groups. 
In a report on hepatic retransplantation Shaw et al found 
that approximately 50% of retransplants in children were for 
rejection:o In our study retransplantation rate for rejection 
was 55% in the steroid group and 37.5% for OKT3 group, but 
was not significant statistically. 
In conclusion. our present study shows that overall infec-
tion rate. rates of viral. fungal and bacterial infections and 
deaths secondary to infection were similar in groups of 
patients receiving OKT3 compared to patients whose rejec· 
tion was treated .... ith only steroids. The retransplantation 
rates for rejection .... ere again not significantly different in 
the two groups. 
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